株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インスリン抵抗性:パイプライン分析

Insulin Resistance - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 245980
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.05円で換算しております。
Back to Top
インスリン抵抗性:パイプライン分析 Insulin Resistance - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 44 Pages
概要

インスリン抵抗性(IR)は、体の細胞がインスリンの効果に耐性を示す状態です。倦怠感、空腹、集中力の欠如、高血圧などの症状が見られます。素因として、肥満や高血圧が挙げられます。

当レポートでは、インスリン抵抗性に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

インスリン抵抗性の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • AUS Bio Limited
  • Genfit SA
  • GlaxoSmithKline Plc
  • Hadasit Medical Research Services & Development Ltd
  • Mertiva AB
  • Mochida Pharmaceutical Co., Ltd.
  • Novartis AG
  • Prometheon Pharma, LLC
  • Sanofi

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • 6860766
  • BVS-857
  • Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis
  • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders
  • elafibranor
  • englerin A
  • MD-960
  • Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders
  • PEG-Catalase
  • Peptide for Obesity and Insulin Resistance
  • SAR-088
  • SERX-1
  • Small Molecule for Hypertension and Insulin Resistance
  • Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation
  • Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders
  • Small Molecule to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular
  • Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders
  • Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders
  • Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9566IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H2 2017, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body's own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Insulin Resistance - Overview
  • Insulin Resistance - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Insulin Resistance - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Insulin Resistance - Companies Involved in Therapeutics Development
  • Amgen Inc
  • AusBio Ltd
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hadasit Medical Research Services & Development Ltd
  • Pfizer Inc
  • Prometheon Pharma LLC
  • Sanofi
  • Insulin Resistance - Drug Profiles
  • ATA-842 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • englerin A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FC-98 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • L-2286 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MD-960 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MD-961 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Agonize Oxytocin Receptor for Obesity and Insulin Resistance - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RG-7992 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-088 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sildenafil citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Target AGTR1 and PPAR Gamma for Hypertension and Insulin Resistance - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit TRIP-Br2 for Obesity and Insulin Resistance - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SYM-401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-25659 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Insulin Resistance - Dormant Projects
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Insulin Resistance, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Insulin Resistance - Pipeline by Amgen Inc, H2 2017
  • Insulin Resistance - Pipeline by AusBio Ltd, H2 2017
  • Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2017
  • Insulin Resistance - Pipeline by Pfizer Inc, H2 2017
  • Insulin Resistance - Pipeline by Prometheon Pharma LLC, H2 2017
  • Insulin Resistance - Pipeline by Sanofi, H2 2017
  • Insulin Resistance - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Insulin Resistance, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top